Oncology Corporate Profile
Portola Pharmaceuticals is focused on the development and commercialization of novel therapeutics to meet patient needs in thrombosis, other hematologic disorders and inflammation. Our current development-stage portfolio includes wholly-owned and partnered products. Portola's wholly-owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways -- spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|cerdulatinib / PTR-2070||dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.||Chronic Lymphocytic Leukemia (CLL)||II|
|cerdulatinib / PTR-2070||dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.||Non-Hodgkin's Lymphoma (NHL)||I|
View additional information on product candidates here »